Results 181 to 190 of about 82,661 (227)

Population pharmacokinetic analysis of letermovir in adult hematopoietic cell transplant recipients. [PDF]

Antimicrob Agents Chemother
Royston L, Kunz C, Tonoli D, Lescuyer P, Neofytos D, Gotta V.   +5 more
europepmc   +1 more source

Dengue-induced pancarditis manifestation of young female with systemic lupus erythematosus: case report. [PDF]

Eur Heart J Case Rep
Hendiperdana MR, Adityansah M, Putri A, Sigit N.   +3 more
europepmc   +1 more source

Keratinocyte-Associated Biomarkers Reveal Pathogenic Mechanisms in Acne. [PDF]

FASEB Bioadv
Cai S, Lin Y, Xie H, Ao X, Liu Q, Huang L.   +5 more
europepmc   +1 more source

Advancing transcriptomics-based mechanistic assessment of nephrotoxicity in vitro using the human RPTEC/TERT1 TXG-MAPr gene co-expression network. [PDF]

Toxicol Sci
van Kessel HW, Kunnen SJ, Callegaro G, van de Water B.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cyclosporine nephrotoxicity

Transplantation Proceedings, 2004
The polypeptide immunosuppressant cyclosporine is a prodrug that binds an intracellular immunophilin. The complex cyclosporine-cyclophilin binds and inhibits the phosphatase activity of calcineurin interfering with the dephosphorilation of members of the nuclear factor of activated T cells, which is involved in the regulation of genes encoding many ...
J M, Grinyó, J M, Cruzado
  +7 more sources

Cyclosporine

Drug Intelligence & Clinical Pharmacy, 1985
Cyclosporine is an immunosuppressant used to prevent the rejection of transplanted kidneys, hearts, and livers. Cyclosporine suppresses T-lymphocyte function without causing myelosuppression, and its pharmacokinetics are highly variable. Compared with conventional immunosuppressive drug therapy, both patient and graft survival improved in patients ...
R J, Ptachcinski, G J, Burckart, R, Venkataramanan   +2 more
openaire   +2 more sources